LXEO:NASDAQLexeo Therapeutics, Inc. analysis
Data as of May 21, 2026 - not real-time
- Latest price
- $5.05
- Risk: high
- 8/10High risk
Summary
Lexeo Therapeutics is trading well below its short‑term and long‑term moving averages, with momentum indicators pointing to a bearish bias. The RSI sits near the neutral‑to‑slightly‑oversold zone, while the MACD histogram is negative, reinforcing short‑term downside pressure.
Despite the technical weakness, the company holds a solid cash position relative to its modest debt, and its pipeline of cardiac and neuro‑genetic gene therapies is advancing through early‑stage trials, supported by collaborations with academic institutions. Analyst consensus is strongly positive, suggesting that upcoming clinical data could serve as a catalyst for a rebound.
Despite the technical weakness, the company holds a solid cash position relative to its modest debt, and its pipeline of cardiac and neuro‑genetic gene therapies is advancing through early‑stage trials, supported by collaborations with academic institutions. Analyst consensus is strongly positive, suggesting that upcoming clinical data could serve as a catalyst for a rebound.
Market outlook
Short term
< 1 yearNeutral
Model confidence6/106 out of 10
Key factors
- Bearish technical positioning relative to moving averages
- Negative MACD momentum
- High short‑term volatility
Medium term
1–3 yearsPositive
Model confidence7/107 out of 10
Key factors
- Upcoming clinical trial readouts for cardiac gene therapies
- Strong cash runway supporting continued R&D
- Analyst consensus indicating strong upside potential
Long term
> 3 yearsPositive
Model confidence8/108 out of 10
Key factors
- Long‑term growth potential of gene‑therapy platform
- Strategic academic collaborations expanding pipeline breadth
- Undervalued price relative to book value and peer multiples
Key metrics
Financial health
P/E Ratio-4.1
ROE-54.75%
ROA-32.50%
Debt/Equity3.18
P/B Ratio1.6
Op. Cash Flow$-97989000
Free Cash Flow$-67344128
Industry P/E26.9
Technical analysis
TrendBearish
RSI40.8
Support$4.43
Resistance$6.43
MA 20$5.58
MA 50$5.89
MA 200$7.15
MACDBearish
VolumeIncreasing
Fear & Greed Index89.79
Valuation
Target Price$19.64
Upside/Downside288.84%
GradeUndervalued
TypeGrowth
Risk assessment
Beta2.02
Volatility80.32%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.